Merit Medical gets breakthrough tag on soft tissue cancer treatment

  Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today the FDA has granted Breakthrough Device Designation for the SCOUT MD Surgical Guidance System.

The SCOUT MD is the latest step in Merit’s ongoing commitment and leadership in advancing oncology care. SCOUT MD expands Merit’s portfolio of products to optimize oncology for breast and other soft tissue cancers, which includes the SCOUT® Radar Localization system with new SCOUT® Mini Reflector and SCOUT Bx™ Delivery System, and the SAVI® Brachy System.

A first of its kind, the SCOUT MD localization system supports implantation of up to four unique reflector configurations. When implanted within abnormal breast or other soft tissue, the reflectors enable surgeons to pinpoint tumor location in multiple dimensions for more precise excision, minimizing trauma to healthy tissue and helping to reduce the likelihood of re-excision and the emotional and physical pain associated with a second surgery.

https://www.biospace.com/article/releases/merit-medical-receives-fda-breakthrough-device-designation-for-the-new-scout-md-surgical-guidance-systemnext-generation-system-helps-improve-surgical-precision-to-enhance-patient-care-in-breast-and-other-soft-tissue-cancer-treatment/